  |
The MedWatch January 2012 Safety Labeling Changes posting includes 63 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.
The "Summary Page" provides a listing of drug names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm289859.htm
The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections:
Accupril (quinapril hydrochloride)
Accuretic (quinapril HCl/ hydrochlorothiazide)
Altace (ramipril)
Avalide (irbesartan/hydrochlorothiazide)
Avapro (irbesartan)
Azor (amlodipine/olmesartan)
Benicar HCT (olmesartan medoxomil/hydrochlorothiazide)
Diovan (valsartan)
Diovan HCT (valsartan/hydrochlorothiazide)
Exforge (amlodipine/valsartan)
Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)
Lotensin (benazapril)
Lotensin HCT (benazapril/hydrochlorothiazide)
Lotrel (amlodipine besylate and benazepril hydrochloride)
Mavik (trandolapril)
Micardis (telmisartan)
Micardis HCT (telmisartan/hydrochlorothiazide)
Tarka (trandolapril/verapamil hydrochloride)
Teveten (eprosartan mesylate)
Teveten HCT (eprosartan mesylate/hydrochlorothiazide)
Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide)
Univasc (moexipril hydrochloride)
Uniretic (moexipril hydrochloride/hydrochlorothiazide)
Ceftriaxone for Injection and Dextrose Injection in Duplex Container
Evoclin (clindamycin phosphate)
Mavik (trandolapril)
Micardis (telmisartan)
Micardis HCT (telmisartan/hydrochlorothiazide)
Micardis HCT (telmisartan/hydrochlorothiazide)
Twynsta (telmisartan/amlodipine)
Xenical (orlistat)
Chantix (varenicline)
Erbitux (cetuximab)
Fanapt (iloperidone)
Fazaclo (clozapine)
Gralise (gabapentin)
Morphine Sulfate Oral Solution,
Morphine Sulfate Tablets
Nexium (esomeprazole sodium)
Nexium (esomeprazole magnesium)
Performist (formoterol fumarate)
Pradaxa (dabigatran etexilate mesylate)
Vimovo (naproxen/esomeprazole magnesium)
Vytorin (ezetimibe/simvastatin)
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
